SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Strategies & Market Trends : Market Gems:Stocks w/Strong Earnings and High Tech. Rank
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Sosmartinov who wrote (74419)12/6/1999 8:14:00 PM
From: Ron  Read Replies (3) of 120523
 
GERN: Could be very interesting tomorrow.
(GERN) The study to be published in tomorrow's issue of the Proceedings of
the National Academy of Sciences validates telomerase as a target for
anti-cancer drug therapy.

?In the experiment, which was carried out for over 100 days, no cells
survived the anti-telomerase treatment. In most current cancer
therapies, there are often some tumor cells that survive the initial
treatment, and this can often lead to cancer relapses,? said Dr. Jerry
Shay one of the collaborators who designed nucleotide sequence .
?Since no cells survived in the study, this indicates that alternative
mechanisms to maintain telomere length were not easily activated.?
--from dayinvestor.com
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News